7 completed, 7 unknown. 7 Phase 1, 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Unknown 2 |
| Phase 2 | 7 | Unknown 6, Completed 1 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
Follow Frontier Biotechnologies Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers Loxoprofen Sodium Patches(reference product), Loxoprofen Sodium Patches(test product ) - Osteoarthritis, Muscle Pain | Phase 1 | Unknown | Frontier Biotechnologies Inc. | 40 | 2024-07-01 | 2024-07-19 |
| Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 FB2001, FB2001 placebo - Mild to Moderate COVID-19 | Phase 2 / Phase 3 | Unknown | Frontier Biotechnologies Inc. | 1336 | 2023-01-04 | 2023-01-09 |
| A Study of FB2001 for Inhalation in Healthy Chinese Adults FB2001 for inhalation, FB2001 for inhalation placebo - COVID-19 Pandemic | Phase 1 | Completed | Frontier Biotechnologies Inc. | 32 | 2022-10-21 | 2023-01-11 |
| Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) FB2001, FB2001 placebo - COVID-19 | Phase 2 / Phase 3 | Unknown | Frontier Biotechnologies Inc. | 1188 | 2022-09-14 | 2023-01-05 |
| Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts FB2001 - Close Contact Transmission | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 60 | 2022-06-09 | 2022-06-13 |
| Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection Albuvirtide - HIV/AIDS | Phase 1 | Completed | Frontier Biotechnologies Inc. | 30 | 2022-02-16 | 2023-01-09 |
| A Bridging Study of FB2001 in Healthy Subjects FB2001, FB2001 placebo - COVID-19 | Phase 1 | Completed | Frontier Biotechnologies Inc. | 40 | 2021-12-29 | 2022-07-06 |
| Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection Albuvirtide, 3BNC117 Antibody - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 20 | 2021-11-30 | 2021-09-29 |
| Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection Albuvirtide, 3BNC117 - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 24 | 2021-05-01 | 2021-03-26 |
| The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection FB2001, FB2001 Placebo - Covid19 | Phase 1 | Completed | Frontier Biotechnologies Inc. | 88 | 2021-03-17 | 2022-11-28 |
| Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects AB001, oral capsule, positive comparative patch - Chronic Low Back Pain | Phase 1 | Completed | Frontier Biotechnologies Inc. | 34 | 2019-06-24 | 2020-03-30 |
| Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects Albuvirtide, 3BNC117, Baseline ART - HIV-1-infection | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 80 | 2018-12-17 | 2021-09-29 |
| A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain AB001 patch, Placebo patch - Chronic Low Back Pain | Phase 2 | Completed | Frontier Biotechnologies Inc. | 146 | 2015-04-01 | 2016-08-30 |
| Test Albuvirtide in Experienced Patients albuvirtide, lopinavir-ritonavir, tenofovir - HIV Infections, AIDS | Phase 3 | Completed | Frontier Biotechnologies Inc. | 418 | 2014-02-19 | 2021-10-06 |
Acquired Immunodeficiency Syndrome (4) · COVID-19 (4) · Coronavirus Infections (1) · HIV Infections (1) · Myalgia (1) · Osteoarthritis (1)
FB2001 (6) · albuvirtide (5) · 3BNC117 antibody (3) · Inhalation (2) · Antibodies, Monoclonal (1) · Capsules (1) · HIV Fusion Inhibitors (1) · Lamivudine (1) · Lopinavir (1) · Tenofovir (1) · Transdermal Patch (1) · lopinavir-ritonavir drug combination (1)
China (8) · United States (4)
Cheng Yao (5) · Changjin Wang (1) · Cheng Yao, M.D. (1) · Dong Xie (1) · Xin Li, PhD (1) · Yun Liu (1)